Page last updated: 2024-11-02

pamidronate and Fibrous Dysplasia, Polyostotic

pamidronate has been researched along with Fibrous Dysplasia, Polyostotic in 25 studies

Fibrous Dysplasia, Polyostotic: FIBROUS DYSPLASIA OF BONE affecting several bones. When melanotic pigmentation (CAFE-AU-LAIT SPOTS) and multiple endocrine hyperfunction are additionally associated it is referred to as Albright syndrome.

Research Excerpts

ExcerptRelevanceReference
"Thirteen patients with McCune-Albright syndrome (MAS) and bone fibrous dysplasia (BFD) have been treated for 2-6 years with pamidronate, an aminobisphosphonate which inhibits osteoclastic function."9.10Pamidronate treatment in bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome. ( Altare, F; Andreo, M; de Sanctis, C; Lala, R; Masi, G; Matarazzo, P, 2002)
"Four infant outcomes of pregnancies of three women, two with polyostotic fibrous dysplasia and one with osteogenesis imperfecta, all of whom were treated with iv pamidronate before conception, are reported, with biochemical, radiological, and bone density data."7.73Maternal and infant outcome after pamidronate treatment of polyostotic fibrous dysplasia and osteogenesis imperfecta before conception: a report of four cases. ( Chan, B; Zacharin, M, 2006)
"An open trial of pamidronate treatment was undertaken in 5 children and 4 young adults with polyostotic fibrous dysplasia associated with McCune Albright syndrome to assess clinical response, bone turnover, and cardiovascular status over a 2-year period."7.70Intravenous pamidronate treatment of polyostotic fibrous dysplasia associated with the McCune Albright syndrome. ( O'Sullivan, M; Zacharin, M, 2000)
"Pamidronate treatment can ameliorate the course of bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome."6.69Pamidronate treatment of bone fibrous dysplasia in nine children with McCune-Albright syndrome. ( Bertelloni, S; Buzi, F; de Sanctis, C; Lala, R; Matarazzo, P; Rigon, F, 2000)
"Pamidronate appears to be an effective and well tolerable treatment option for patients with fibrous dysplasia."5.30[Effect of pamidronate on clinical symptoms and bone metabolism in fibrous dysplasia and McCune-Albright syndrome]. ( Pfeilschifter, J; Ziegler, R, 1998)
"Thirteen patients with McCune-Albright syndrome (MAS) and bone fibrous dysplasia (BFD) have been treated for 2-6 years with pamidronate, an aminobisphosphonate which inhibits osteoclastic function."5.10Pamidronate treatment in bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome. ( Altare, F; Andreo, M; de Sanctis, C; Lala, R; Masi, G; Matarazzo, P, 2002)
"ALP = alkaline phosphatase; β-CTX = C-terminal telopeptide of type I collagen; BP = bisphosphonate; BTM = bone turnover marker; FD = fibrous dysplasia; MAS = McCune-Albright syndrome; ONJ = osteonecrosis of the jaw; PAM = pamidronate; PFD = polyostotic fibrous dysplasia; ULN = upper limit of normal; ZA = zoledronic acid."3.91EFFICACY AND SAFETY OF BISPHOSPHONATE THERAPY IN MCCUNE-ALBRIGHT SYNDROME-RELATED POLYOSTOTIC FIBROUS DYSPLASIA: A SINGLE-CENTER EXPERIENCE. ( Jiang, Y; Li, M; Meng, X; Wang, O; Wang, Y; Xia, W; Xing, X, 2019)
" We report here on a child with McCune-Albright syndrome (FD in addition to hyperfunctioning endocrinopathies and skin hyperpigmentation) treated with cyclical intravenous infusions of pamidronate in which conventional radiography, contact microradiography, histology, and backscattered electron image analysis demonstrated that zebra lines formed only where bone was normal, were arrested at the boundary between FD-unaffected and FD-affected bone where bone is sclerotic, and were absent within the undermineralized FD bone."3.85Bisphosphonate-induced zebra lines in fibrous dysplasia of bone: histo-radiographic correlation in a case of McCune-Albright syndrome. ( Boyde, A; Corsi, A; Ippolito, E; Riminucci, M; Robey, PG, 2017)
"To examine outcomes of pamidronate treatment on fibrous dysplasia of bone in three children with McCune-Albright syndrome (MAS)."3.73Pamidronate treatment of polyostotic fibrous dysplasia: failure to prevent expansion of dysplastic lesions during childhood. ( Chan, B; Zacharin, M, 2006)
"Four infant outcomes of pregnancies of three women, two with polyostotic fibrous dysplasia and one with osteogenesis imperfecta, all of whom were treated with iv pamidronate before conception, are reported, with biochemical, radiological, and bone density data."3.73Maternal and infant outcome after pamidronate treatment of polyostotic fibrous dysplasia and osteogenesis imperfecta before conception: a report of four cases. ( Chan, B; Zacharin, M, 2006)
"Intravenous infusions with the bisphosphonate compound pamidronate decrease bone pain and reportedly can lead to refilling of dysplastic lesions in adults with fibrous dysplasia (FD) of bone."3.72Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone. ( Glorieux, FH; Munns, C; Plotkin, H; Rauch, F; Travers, R; Zeitlin, L, 2003)
"An open trial of pamidronate treatment was undertaken in 5 children and 4 young adults with polyostotic fibrous dysplasia associated with McCune Albright syndrome to assess clinical response, bone turnover, and cardiovascular status over a 2-year period."3.70Intravenous pamidronate treatment of polyostotic fibrous dysplasia associated with the McCune Albright syndrome. ( O'Sullivan, M; Zacharin, M, 2000)
"One of the main features of McCune-Albright syndrome is bone fibrous dysplasia (BFD) often associated with severe clinical outcomes, such as bone pain, bone deformities and pathological fractures."2.72Bisphosphonate treatment of bone fibrous dysplasia in McCune-Albright syndrome. ( Andreo, M; Bellone, J; Corrias, A; de Sanctis, C; Lala, R; Marzari, D; Matarazzo, P, 2006)
"Pamidronate treatment can ameliorate the course of bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome."2.69Pamidronate treatment of bone fibrous dysplasia in nine children with McCune-Albright syndrome. ( Bertelloni, S; Buzi, F; de Sanctis, C; Lala, R; Matarazzo, P; Rigon, F, 2000)
"Fibrous dysplasia of bone is a genetic, non-inheritable disease, characterized by bone pain, bone deformities and fracture, involving one or several bones."2.44Fibrous dysplasia of bone and McCune-Albright syndrome. ( Chapurlat, RD; Orcel, P, 2008)
"Fibrous dysplasia of bone is a disease that can involve one or several bones and is characterized by bone deformities, pain and iterative fractures."2.41Fibrous dysplasia of bone. ( Chapurlat, RD; Meunier, PJ, 2000)
"McCune-Albright syndrome (MAS) typically comprises the constellation of polyostotic fibrous dysplasia, café-au-lait spots, and associated endocrinopathies including gonadotropin-independent precocious puberty, excessive growth hormone production and gigantism, hyperthyroidism, and hyperparathyroidism."1.36Unusual phenotypical variations in a boy with McCune-Albright syndrome. ( Anhalt, H; Mamkin, I; Philibert, P; Sultan, C; Ten, S, 2010)
"McCune-Albright syndrome (MAS) is sometimes complicated by hypophosphatemia and abnormally low levels of 1,25(OH)(2)D in the presence of hypophosphatemia."1.33The role of fibroblast growth factor 23 for hypophosphatemia and abnormal regulation of vitamin D metabolism in patients with McCune-Albright syndrome. ( Imanishi, Y; Inaba, M; Jüppner, H; Kinoshita, E; Koshiyama, H; Miyauchi, A; Nakagomi, Y; Nishizawa, Y; Ozono, K; Satomura, K; Shimizu, N; Yamamoto, T, 2005)
"We describe a rare case of polyostotic fibrous dysplasia with craniofacial localisation associated with the involvement of the humerus in a 65-year-old female patient."1.33[A case of polyostotic fibrous dysplasia]. ( Jaworska, M; Klempous, J; Kuźniar, J; Sztuka, A, 2006)
"pamidronate was given for 6 months."1.31[Fibrous dysplasia: differential diagnosis from Paget's disease]. ( Heilmann, P; Kasperk, Ch; Nawroth, P; Schulz, A; Wagner, P, 2002)
"McCune-Albright syndrome is a rare syndrome presenting with polyostotic dysplasia, cafe-au-lait spots and multiple endocrinopathies that is very often combined with precocious puberty."1.31Clinical, endocrinological and radiography features in a child with McCune-Albright syndrome and pituitary adenoma. ( Jassoy, A; Lebek, S; Nagel, M; Zumkeller, W, 2001)
"Pamidronate appears to be an effective and well tolerable treatment option for patients with fibrous dysplasia."1.30[Effect of pamidronate on clinical symptoms and bone metabolism in fibrous dysplasia and McCune-Albright syndrome]. ( Pfeilschifter, J; Ziegler, R, 1998)

Research

Studies (25)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (4.00)18.2507
2000's17 (68.00)29.6817
2010's7 (28.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bachelet, JT1
Mendes, LC1
Delafond, C1
Barba, T1
Gleizal, A1
Paulus, C1
Corsi, A1
Ippolito, E1
Robey, PG1
Riminucci, M1
Boyde, A1
Wang, Y1
Wang, O1
Jiang, Y1
Li, M1
Xia, W1
Meng, X1
Xing, X1
Couturier, A1
Aumaître, O1
Gilain, L1
Jean, B1
Mom, T1
André, M1
Mamkin, I1
Philibert, P1
Anhalt, H1
Ten, S1
Sultan, C1
Kochar, IP1
Kulkarni, KP1
Rastogi, A1
Bhadada, SK1
Bhansali, A1
Matarazzo, P4
Lala, R4
Masi, G1
Andreo, M3
Altare, F1
de Sanctis, C4
Isaia, GC1
Defilippi, C1
Roggia, C1
Priolo, G1
Wagner, P1
Heilmann, P1
Schulz, A1
Nawroth, P1
Kasperk, Ch1
Saenger, P1
Rincon, M1
Plotkin, H1
Rauch, F1
Zeitlin, L1
Munns, C1
Travers, R1
Glorieux, FH1
Yamamoto, T1
Imanishi, Y1
Kinoshita, E1
Nakagomi, Y1
Shimizu, N1
Miyauchi, A1
Satomura, K1
Koshiyama, H1
Inaba, M1
Nishizawa, Y1
Jüppner, H1
Ozono, K1
Chan, B2
Zacharin, M3
Klempous, J1
Kuźniar, J1
Sztuka, A1
Jaworska, M1
Bieniasz, J1
Maj, A1
Noczyńska, A1
Marzari, D1
Bellone, J1
Corrias, A1
Chapurlat, RD2
Orcel, P1
Pfeilschifter, J1
Ziegler, R1
Bertelloni, S1
Buzi, F1
Rigon, F1
Meunier, PJ1
O'Sullivan, M1
Zumkeller, W1
Jassoy, A1
Lebek, S1
Nagel, M1
Parisi, MS1
Oliveri, MB1
Mautalen, CA1

Reviews

2 reviews available for pamidronate and Fibrous Dysplasia, Polyostotic

ArticleYear
Fibrous dysplasia of bone and McCune-Albright syndrome.
    Best practice & research. Clinical rheumatology, 2008, Volume: 22, Issue:1

    Topics: Diphosphonates; Fibrous Dysplasia of Bone; Fibrous Dysplasia, Polyostotic; Fractures, Bone; GTP-Bind

2008
Fibrous dysplasia of bone.
    Bailliere's best practice & research. Clinical rheumatology, 2000, Volume: 14, Issue:2

    Topics: Adolescent; Anti-Inflammatory Agents; Diphosphonates; Fibrous Dysplasia of Bone; Fibrous Dysplasia,

2000

Trials

4 trials available for pamidronate and Fibrous Dysplasia, Polyostotic

ArticleYear
Pamidronate treatment in bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome.
    Journal of pediatric endocrinology & metabolism : JPEM, 2002, Volume: 15 Suppl 3

    Topics: Adolescent; Adult; Alkaline Phosphatase; Body Height; Bone and Bones; Bone Density; Child; Diphospho

2002
Bone turnover in children and adolescents with McCune-Albright syndrome treated with pamidronate for bone fibrous dysplasia.
    Calcified tissue international, 2002, Volume: 71, Issue:2

    Topics: Adolescent; Adult; Alkaline Phosphatase; Anti-Inflammatory Agents; Bone and Bones; Bone Density; Bon

2002
Bisphosphonate treatment of bone fibrous dysplasia in McCune-Albright syndrome.
    Journal of pediatric endocrinology & metabolism : JPEM, 2006, Volume: 19 Suppl 2

    Topics: Adolescent; Alkaline Phosphatase; Bone Density Conservation Agents; Child; Child, Preschool; Diphosp

2006
Pamidronate treatment of bone fibrous dysplasia in nine children with McCune-Albright syndrome.
    Acta paediatrica (Oslo, Norway : 1992), 2000, Volume: 89, Issue:2

    Topics: Adolescent; Bone Density; Child; Child, Preschool; Diphosphonates; Female; Fibrous Dysplasia of Bone

2000

Other Studies

19 other studies available for pamidronate and Fibrous Dysplasia, Polyostotic

ArticleYear
Giant Hemifacial Fibrous Dysplasia Functional Treatment and Place of Pamidronate.
    The Journal of craniofacial surgery, 2017, Volume: 28, Issue:3

    Topics: Bone Density Conservation Agents; Child; Diphosphonates; Dose-Response Relationship, Drug; Facial Bo

2017
Bisphosphonate-induced zebra lines in fibrous dysplasia of bone: histo-radiographic correlation in a case of McCune-Albright syndrome.
    Skeletal radiology, 2017, Volume: 46, Issue:10

    Topics: Adolescent; Diphosphonates; Disease Progression; Female; Femur; Fibrous Dysplasia, Polyostotic; Huma

2017
EFFICACY AND SAFETY OF BISPHOSPHONATE THERAPY IN MCCUNE-ALBRIGHT SYNDROME-RELATED POLYOSTOTIC FIBROUS DYSPLASIA: A SINGLE-CENTER EXPERIENCE.
    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2019, Volume: 25, Issue:1

    Topics: Bone and Bones; Diphosphonates; Fibrous Dysplasia, Polyostotic; Humans; Pamidronate; Retrospective S

2019
Craniofacial fibrous dysplasia: A 10-case series.
    European annals of otorhinolaryngology, head and neck diseases, 2017, Volume: 134, Issue:4

    Topics: Adolescent; Adult; Aged; Bone Density Conservation Agents; Child; Diagnosis, Differential; Diphospho

2017
Unusual phenotypical variations in a boy with McCune-Albright syndrome.
    Hormone research in paediatrics, 2010, Volume: 73, Issue:3

    Topics: Base Sequence; Child; Diphosphonates; Fibrous Dysplasia, Polyostotic; Fractures, Bone; Growth Disord

2010
Pamidronate for fibrous dysplasia due to McCune Albright Syndrome.
    Indian pediatrics, 2010, Volume: 47, Issue:7

    Topics: Ankle; Bone Density Conservation Agents; Child; Child, Preschool; Diphosphonates; Female; Fibrous Dy

2010
Recurrent femur neck fracture and response to bisphosphonates in polyostotic fibrous dysplasia.
    Indian journal of pediatrics, 2012, Volume: 79, Issue:5

    Topics: Adolescent; Bone Density Conservation Agents; Diphosphonates; Female; Femoral Neck Fractures; Fibrou

2012
[Fibrous dysplasia: differential diagnosis from Paget's disease].
    Deutsche medizinische Wochenschrift (1946), 2002, Oct-25, Volume: 127, Issue:43

    Topics: Absorptiometry, Photon; Adult; Anti-Inflammatory Agents; Biopsy; Bone Diseases, Metabolic; Diagnosis

2002
Precocious puberty: McCune-Albright syndrome and beyond.
    The Journal of pediatrics, 2003, Volume: 143, Issue:1

    Topics: Anti-Inflammatory Agents; Central Nervous System Neoplasms; Child; Child, Preschool; Diphosphonates;

2003
Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone.
    The Journal of clinical endocrinology and metabolism, 2003, Volume: 88, Issue:10

    Topics: Adolescent; Alkaline Phosphatase; Anti-Inflammatory Agents; Biomarkers; Biopsy; Body Height; Calcium

2003
The role of fibroblast growth factor 23 for hypophosphatemia and abnormal regulation of vitamin D metabolism in patients with McCune-Albright syndrome.
    Journal of bone and mineral metabolism, 2005, Volume: 23, Issue:3

    Topics: Adolescent; Adult; Calcium; Child; Diphosphonates; Female; Fibroblast Growth Factor-23; Fibroblast G

2005
Pamidronate treatment of polyostotic fibrous dysplasia: failure to prevent expansion of dysplastic lesions during childhood.
    Journal of pediatric endocrinology & metabolism : JPEM, 2006, Volume: 19, Issue:1

    Topics: Adolescent; Bone and Bones; Bone Density Conservation Agents; Child; Child, Preschool; Diphosphonate

2006
Maternal and infant outcome after pamidronate treatment of polyostotic fibrous dysplasia and osteogenesis imperfecta before conception: a report of four cases.
    The Journal of clinical endocrinology and metabolism, 2006, Volume: 91, Issue:6

    Topics: Adult; Bone and Bones; Calcium; Diphosphonates; Female; Fetus; Fibrous Dysplasia, Polyostotic; Human

2006
[A case of polyostotic fibrous dysplasia].
    Wiadomosci lekarskie (Warsaw, Poland : 1960), 2006, Volume: 59, Issue:1-2

    Topics: Aged; Anti-Inflammatory Agents; Diphosphonates; Female; Fibrous Dysplasia, Polyostotic; Humans; Pami

2006
[Fibrous dysplasia of bone in a 12-year old girl].
    Endokrynologia, diabetologia i choroby przemiany materii wieku rozwojowego : organ Polskiego Towarzystwa Endokrynologow Dzieciecych, 2006, Volume: 12, Issue:1

    Topics: Adolescent; Bone Density Conservation Agents; Diagnosis, Differential; Diphosphonates; Female; Fibro

2006
[Effect of pamidronate on clinical symptoms and bone metabolism in fibrous dysplasia and McCune-Albright syndrome].
    Medizinische Klinik (Munich, Germany : 1983), 1998, Jun-15, Volume: 93, Issue:6

    Topics: Adolescent; Adult; Anti-Inflammatory Agents; Bone and Bones; Child; Diphosphonates; Female; Fibrous

1998
Intravenous pamidronate treatment of polyostotic fibrous dysplasia associated with the McCune Albright syndrome.
    The Journal of pediatrics, 2000, Volume: 137, Issue:3

    Topics: Adolescent; Adult; Bone and Bones; Bone Density; Cardiac Output; Child; Child, Preschool; Diphosphon

2000
Clinical, endocrinological and radiography features in a child with McCune-Albright syndrome and pituitary adenoma.
    Journal of pediatric endocrinology & metabolism : JPEM, 2001, Volume: 14, Issue:5

    Topics: Adenoma; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Child; Diphosphonates; Drug Therapy

2001
Bone mineral density response to long-term bisphosphonate therapy in fibrous dysplasia.
    Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry, 2001,Summer, Volume: 4, Issue:2

    Topics: Absorptiometry, Photon; Adult; Bone Density; Diphosphonates; Female; Fibrous Dysplasia, Polyostotic;

2001